Profile data is unavailable for this security.
About the company
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
- Revenue in USD (TTM)8.55m
- Net income in USD-27.62m
- Incorporated1998
- Employees58.00
- LocationDURECT Corp10240 Bubb RoadCUPERTINO 95014United StatesUSA
- Phone+1 (408) 777-1417
- Fax+1 (408) 777-3577
- Websitehttps://www.durect.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc | 2.24m | -42.19m | 36.35m | 57.00 | -- | 0.6344 | -- | 16.23 | -7.18 | -7.18 | 0.4056 | 6.21 | 0.0332 | -- | 0.8059 | 39,280.53 | -62.58 | -- | -77.39 | -- | -- | -- | -1,884.50 | -- | -- | -- | 0.0743 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Estrella Immunopharma Inc | 0.00 | -2.16m | 36.61m | -- | -- | 3.50 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
| Marker Therapeutics Inc | 3.31m | -14.05m | 36.63m | 8.00 | -- | 2.60 | -- | 11.06 | -1.59 | -0.933 | 0.3753 | 1.58 | 0.1285 | -- | 1.93 | 413,892.50 | -54.49 | -53.74 | -69.03 | -62.25 | -- | -- | -424.20 | -1,438.71 | -- | -- | 0.00 | -- | -5.76 | 74.27 | 28.97 | -- | -- | -- |
| Incannex Healthcare Inc | 163.39k | -13.70m | 36.67m | -- | -- | 1.94 | -- | 224.41 | -0.3806 | -0.3806 | 0.0003 | 1.19 | 0.0038 | -- | 0.0554 | -- | -31.42 | -54.94 | -32.90 | -59.47 | -- | -- | -8,386.19 | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 36.80m | 1.00 | -- | 0.2055 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 33.88m | -26.96m | 36.85m | 176.00 | -- | 1.52 | -- | 1.09 | -2.02 | -2.02 | 2.54 | 1.81 | 0.3951 | 1.26 | 3.01 | 192,494.30 | -30.57 | -34.75 | -45.42 | -46.91 | 59.19 | 55.98 | -77.37 | -153.72 | 2.60 | -- | 0.4388 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| OncoCyte Corp | 1.50m | -25.80m | 37.02m | 43.00 | -- | 1.12 | -- | 24.63 | -3.08 | -3.47 | 0.1869 | 3.10 | 0.0172 | -- | 1.20 | 34,953.49 | -28.41 | -35.11 | -31.93 | -39.71 | 27.48 | -- | -1,653.69 | -2,373.36 | -- | -146.07 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Janone Inc | 0.00 | -17.10m | 37.07m | 5.00 | -- | -- | -- | -- | -3.52 | -0.4564 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.40 | -23.12 | -96.58 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.0594 | -- | -- | -- | -313.15 | -- | -- | -- |
| DURECT Corp | 8.55m | -27.62m | 37.24m | 58.00 | -- | 2.46 | -- | 4.36 | -1.12 | -1.12 | 0.3257 | 0.4873 | 0.1624 | 0.7927 | 3.65 | 147,379.30 | -52.47 | -37.34 | -124.79 | -53.44 | 79.91 | 91.83 | -323.16 | -139.11 | 1.20 | -55.63 | 0.5299 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Rapid Micro Biosystems Inc | 23.10m | -51.90m | 37.58m | 193.00 | -- | 0.3541 | -- | 1.63 | -1.20 | -1.20 | 0.5355 | 2.48 | 0.1535 | 1.37 | 4.34 | 119,663.20 | -34.49 | -- | -38.20 | -- | -22.59 | -- | -224.73 | -- | 5.62 | -- | 0.0028 | -- | 31.44 | -- | 13.71 | -- | -- | -- |
| Apollomics Inc | 0.00 | -677.48k | 37.58m | -- | -- | 0.0449 | -- | -- | -0.0505 | -0.0505 | 0.00 | 9.36 | 0.00 | -- | -- | -- | -0.6357 | -- | -0.6538 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -281.92 | -- | -- | -- |
| China Health Industries Holdings, Inc. | 117.28k | -1.51m | 38.01m | 32.00 | -- | -- | -- | 324.12 | -0.023 | -0.023 | 0.0018 | -0.0349 | 0.0044 | 0.5692 | 25.25 | 3,665.00 | -5.72 | 3.04 | -7.60 | 3.66 | -2.37 | 69.55 | -1,287.13 | 28.61 | 0.0377 | -- | 1.68 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Vyne Therapeutics Inc | 424.00k | -27.87m | 38.21m | 10.00 | -- | 0.4306 | -- | 90.11 | -6.84 | -7.00 | 0.0413 | 6.29 | 0.0061 | -- | 0.1639 | 42,400.00 | -40.27 | -108.41 | -45.86 | -138.57 | -- | -- | -6,573.82 | -1,907.10 | -- | -- | 0.00 | -- | -11.11 | -47.51 | 17.89 | -- | -- | -- |
| Natural Alternatives International, Inc. | 127.76m | -4.11m | 38.36m | 317.00 | -- | 0.4489 | 85.24 | 0.3002 | -0.705 | -0.705 | 21.87 | 14.03 | 0.8624 | 4.23 | 12.32 | 403,041.00 | -2.77 | 4.90 | -3.11 | 5.93 | 7.90 | 15.98 | -3.22 | 3.80 | 2.59 | -2.54 | 0.0988 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| Bright Green Corp | 0.00 | -13.13m | 38.70m | 5.00 | -- | 3.43 | -- | -- | -0.0732 | -0.0732 | 0.00 | 0.0594 | 0.00 | -- | -- | 0.00 | -64.24 | -- | -97.68 | -- | -- | -- | -- | -- | -- | -5,488.51 | 0.0181 | -- | -- | -- | 52.54 | -- | -- | -- |
Data as of May 07 2024. Currency figures normalised to DURECT Corp's reporting currency: US Dollar USD
19.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Ingalls & Snyder LLCas of 31 Dec 2023 | 2.15m | 7.19% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.06m | 3.57% |
| Richmond Brothers, Inc.as of 31 Dec 2023 | 518.29k | 1.74% |
| Gagnon Securities LLCas of 31 Dec 2023 | 358.71k | 1.20% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 334.30k | 1.12% |
| Beirne Wealth Consulting Services LLCas of 31 Dec 2023 | 320.05k | 1.07% |
| GSA Capital Partners LLPas of 31 Mar 2024 | 241.67k | 0.81% |
| Dalton Investments LLCas of 31 Dec 2023 | 237.33k | 0.80% |
| Geode Capital Management LLCas of 31 Dec 2023 | 234.36k | 0.79% |
| Tocqueville Asset Management LPas of 31 Dec 2023 | 231.22k | 0.78% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
